Polaris AI Pharma announced on January 15 that Alpha Tau Medical (hereafter Alpha Tau), a Nasdaq-listed company in which it has made a strategic investment, unveiled groundbreaking clinical results for pancreatic cancer at two of the global biotech industry's leading events: the JP Morgan Healthcare Conference (JPMHC) and the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium).
Alpha Tau participated in both the 44th JPM Healthcare Conference, the world's largest pharmaceutical and biotech investment event held in early January in San Francisco, and ASCO GI 2026, the most prestigious academic conference in the field of gastrointestinal cancers.
At these two events, Alpha Tau attracted significant attention from both academia and investors by releasing final clinical data on pancreatic cancer from Montreal, utilizing its proprietary technology, Alpha DaRT (Alpha Diffusing Alpha-emitters Radiation Therapy).
The core of the announcement was the demonstration of an "immune-preservation" effect, going beyond the simple eradication of cancer cells.
According to the released data, pancreatic cancer patients treated with Alpha DaRT achieved a high disease control rate (DCR) of 87% (excluding the initial safety patient cohort), while the number of lymphocytes and the proportion of T cells-both indicators of the body's immune function-remained stably maintained at pre-treatment levels.
This means that Alpha DaRT has overcome the critical drawback of conventional radiation therapy, which destroys not only cancer cells but also healthy immune cells.
The company stated, "It has been validated at global academic conferences that Alpha DaRT can necrotize tumors with powerful alpha particles while fully preserving the patient's systemic immune system," adding, "This serves as a strong rationale for potential synergy in combination therapies with immuno-oncology drugs such as Keytruda in the future."
Polaris AI Pharma is focusing on the fact that Alpha Tau received positive feedback at both JPM (investment) and ASCO (academic), two major global events, and expects this to lead to a revaluation of the company's value.
In particular, at the JPM conference, it was reported that numerous partnership meetings with global big pharma companies took place based on these immune-preservation data, signaling a positive outlook for the value of Polaris AI Pharma's equity stake as an investor.
A representative from Polaris AI Pharma stated, "Alpha Tau has demonstrated both technological excellence and commercial value on the world stage at JPM and ASCO GI. As our partner's global standing rises with these achievements, we expect Polaris AI Pharma's proactive investment to translate into an increase in equity value and enhanced shareholder value."
Meanwhile, Polaris AI Pharma continues to operate its generic-based API and CDMO businesses stably. Since joining the Polaris Group, the company has also been expanding into AI-driven pharmaceutical research and development (R&D) data businesses focused on software, in collaboration with Polaris Office.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
